✦ LIBER ✦

The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)

✍ Scribed by Susanne Taucher; Guenther G. Steger; Raimund Jakesz; Christoph Tausch; Viktor Wette; Walter Schippinger; Werner Kwasny; Georg Reiner; Richard Greil; Peter Dubsky; Sabine Poestlberger; Joerg Tschmelitsch; Hellmut Samonigg; Michael Gnant

Publisher: Springer US
Year: 2007
Tongue: English
Weight: 252 KB
Volume: 112
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-007-9844-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Exemestane as primary systemic treatment

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

✍ Brigitte Mlineritsch; Christoph Tausch; Christian Singer; Gero Luschin-Ebengreut 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB

Randomized adjuvant trial to evaluate th

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

A single-center, prospective and randomi

A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?

✍ Meijun Long; Weijuan Jia; Shunrong Li; Liang Jin; Jiannan Wu; Nanyan Rao; Huiyi 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 188 KB

Results of the first phase 1 clinical tr

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients : United States Military Cancer Institute Clinical Trials Group Study I-04

✍ Mark G. Carmichael; Linda C. Benavides; Jarrod P. Holmes; Jeremy D. Gates; Eliza 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Decreased immunoreactivity for p27 prote

Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status : Results from International Breast Cancer Study Group Trial V

✍ Vito J. Spataro; Heather Litman; Giuseppe Viale; Fausto Maffini; Michele Masullo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to clarify the prognostic and predictive value of immunoreactivity for the cyclin‐dependent kinase inhibitor p27(Kip1) in patients with early‐stage breast carcinoma and to investigate its relation with clinicopathologic features and other m

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views